Key Takeaways

• Hybridoma technology fuses a B cell with a myeloma cell to make an immortal, antibody-producing hybrid.
• It was invented by Köhler and Milstein in 1975 and won the 1984 Nobel Prize.
• Each hybridoma clone produces a single monoclonal antibody of defined specificity.
• HAT medium selects successfully fused hybridomas from unfused cells.
• Monoclonal antibodies underpin diagnostics, therapeutics, research and vaccine development.
• Chimeric, humanised and recombinant methods now extend and complement the original technique.

Contents

• What is Hybridoma Technology?
• How Hybridomas Are Made
• Selecting and Screening Hybridomas
• Applications of Monoclonal Antibodies
• Challenges and Modern Alternatives
• Frequently Asked Questions

Antibodies & Reagents for Hybridoma Workflows

From screening secondary antibodies to validated monoclonal and tag antibodies, these reagents support every stage of monoclonal antibody development and detection.

Anti-Mouse HRP

HRP Goat Anti-Mouse IgG

Secondary AbHRP

A workhorse secondary for ELISA screening of mouse hybridoma supernatants.

View antibody →

Anti-Rabbit HRP

HRP Goat Anti-Rabbit IgG

Secondary AbHRP

HRP-conjugated secondary for detecting rabbit primary antibodies in screening assays.

View antibody →

Anti-GFP

GFP Monoclonal Antibody

MonoclonalWB · IF

A high-specificity monoclonal — a typical product of the hybridoma approach.

View antibody →

Anti-His HRP

Anti-His-Tag Monoclonal (HRP)

MonoclonalHRP

Directly conjugated anti-His mAb for detecting recombinant tagged proteins.

View antibody →

Anti-HA

HA-Tag Monoclonal Antibody

MonoclonalWB · IP

A clonal anti-tag antibody for tracking HA-tagged fusion proteins.

View antibody →

IgG1 Control

IgG1 Isotype Control

Isotype ControlPurified

A matched negative control to confirm specific antibody binding.

View antibody →

What is Hybridoma Technology?

Hybridoma technology is a method for producing large quantities of identical antibodies, known as monoclonal antibodies, from a single clone of cells. It was pioneered by Georges Köhler and César Milstein in 1975 — work so influential that it earned them the Nobel Prize in Physiology or Medicine in 1984 — and it fundamentally transformed immunology, diagnostics and drug development.

The breakthrough was solving a long-standing problem: antibody-producing B cells cannot survive for long in culture, so it was impossible to obtain a steady supply of a single defined antibody. By fusing a B cell with an immortal cancer cell, Köhler and Milstein created a hybrid — a hybridoma — that combined the antibody-making ability of the B cell with the endless proliferation of the tumour cell.

How Hybridomas Are Made

The process begins by immunising a small mammal, typically a mouse, with a specific antigen. The animal mounts an immune response, and its spleen becomes rich in B cells producing antibodies against that antigen. These B cells are harvested and fused with myeloma (immortal plasma-tumour) cells, usually using polyethylene glycol to merge their membranes.

The fusion yields a mixture of cells: unfused B cells, unfused myeloma cells, and the desired hybridomas. Each hybridoma inherits two crucial traits — the antibody-producing capability of the B cell and the immortality of the myeloma cell — so it can be cultured indefinitely while secreting a single, defined antibody.

Selecting and Screening Hybridomas

Because fusion is inefficient, the next step is to select only the hybridomas from the mixture. This is done in HAT medium (hypoxanthine, aminopterin and thymidine). The myeloma cells used are deficient in the enzyme HGPRT, so aminopterin blocks their DNA synthesis and they die; unfused B cells die naturally in culture; only the fused hybridomas, which gain a functional HGPRT gene from the B cell, survive.

Surviving hybridomas are then diluted to single cells, grown into clonal populations, and screened — typically by ELISA — to identify the clones producing the antibody of interest. Secondary antibodies such as HRP-conjugated anti-mouse IgG provide the detection signal in these screening plates. The best clones are expanded and banked as a permanent, renewable source of that monoclonal antibody.

Applications of Monoclonal Antibodies

The monoclonal antibodies produced by hybridomas are among the most versatile tools in biology and medicine.

Medical diagnostics

Their exquisite specificity makes monoclonal antibodies ideal for detecting disease markers in ELISA, lateral-flow and immunohistochemistry tests — from pregnancy tests to cancer biomarkers.

Therapeutics

Therapeutic monoclonal antibodies now treat cancers, autoimmune diseases and infections by precisely targeting disease-associated molecules, a cornerstone of modern precision medicine.

Basic research

In the laboratory, monoclonal antibodies are indispensable for Western blotting, flow cytometry, immunofluorescence and immunoprecipitation, illuminating where and when proteins are expressed.

Vaccine development

Monoclonals aid the identification and characterisation of antigens, helping researchers understand the immune response and improve vaccine design.

Challenges and Modern Alternatives

While hybridoma technology was a giant leap forward, it has limitations. Antibodies raised in mice can provoke an immune reaction when given to humans, and the fusion and screening process is laborious. To address immunogenicity, chimeric antibodies (with human constant regions) and fully humanised antibodies (with human variable and constant regions) were developed, greatly reducing adverse reactions.

In parallel, antibody-engineering approaches such as phage display and recombinant DNA technology now complement — and in some cases replace — the classical hybridoma. These methods can generate antibodies without immunising animals and offer additional routes to refine affinity and specificity, giving researchers a broader toolkit than ever for producing the perfect antibody.